logo
Plus   Neg
Share
Email

Curis Begins Phase 1 Trial Of CA-4948 In Patients With Lymphomas - Quick Facts

Curis, Inc. (CRIS) announced initiation of patient dosing in a Phase 1 trial of CA-4948, an orally available small molecule inhibitor of the IRAK4 kinase, for treatment of patients with lymphoma. The Phase 1 study is designed to evaluate the safety, tolerability, and pharmacokinetic profile of CA-4948; identify any dose-limiting toxicities; and establish the recommended Phase 2 dose for the treatment of patients with lymphomas.

CA-4948 was discovered at Aurigene and is the second licensed program from the Curis-Aurigene collaboration to enter the clinic.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The United Auto Workers union on Sunday called for a strike at General Motors at midnight after both the parties failed to reach a tentative deal before a Saturday deadline. The last time the union declared a strike at GM was in 2007. General Motors has detailed its most recent offer, including 5,400 jobs and $7 billion in investment at its US plants. The United Auto Workers union reportedly plans to go on strike against auto giant General Motors Co. (GM) after both the parties failed to reach a tentative deal before a Saturday deadline. According to CNBC, the strike has been called despite GM saying it presented a "strong offer" to the union.... Millennials and Generation Zs, or people aged between 18 to 34 year, pay more for car repairs, according to a new survey. The average American spent $1,986 over the past five years on vehicle repairs and maintenance, according to a survey by Ally Financial conducted by Harris Poll. However, among...
Follow RTT